HEPA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
HEPA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Hepion Pharmaceuticals's basic earnings per share (Basic EPS) for the three months ended in Dec. 2023 was $-2.42. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.32.
Hepion Pharmaceuticals's EPS (Diluted) for the three months ended in Dec. 2023 was $-2.42. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-12.32.
Hepion Pharmaceuticals's EPS without NRI for the three months ended in Dec. 2023 was $-1.49. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was -11.44.
During the past 3 years, the average EPS without NRI Growth Rate was 35.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was 63.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 11 years, Hepion Pharmaceuticals's highest 3-Year average EPS without NRI Growth Rate was 84.80% per year. The lowest was -41.40% per year. And the median was 55.00% per year.
The historical data trend for Hepion Pharmaceuticals's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hepion Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Jun14 | Jun15 | Jun16 | Jun17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EPS (Basic) | Get a 7-Day Free Trial | -122.20 | -42.00 | -9.40 | -11.90 | -12.32 |
Hepion Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EPS (Basic) | Get a 7-Day Free Trial | -2.62 | -3.48 | -3.68 | -2.74 | -2.42 |
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Hepion Pharmaceuticals's Basic EPS for the fiscal year that ended in Dec. 2023 is calculated as
Basic EPS (A: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-48.926 | - | 0) | / | 3.971 | |
= | -12.32 |
Hepion Pharmaceuticals's Basic EPS for the quarter that ended in Dec. 2023 is calculated as
Basic EPS (Q: Dec. 2023 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-11.06 | - | 0) | / | 4.407 | |
= | -2.51 |
EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.32
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hepion Pharmaceuticals (NAS:HEPA) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of Hepion Pharmaceuticals's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Wijngaard | director | 8 SYLVAN WAY, PARSIPPANY NJ 07054 |
Robert T Foster | officer: Chief Scientific Officer | C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
Kaouthar Lbiati | director | 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
Anand Reddi | director | 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837 |
John T Cavan | officer: Chief Financial Officer | C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022 |
John P Brancaccio | director | C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852 |
Gary S Jacob | director, officer: CEO and President | |
Donald E Garlikov | 10 percent owner | 41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215 |
Tamar D Howson | director | |
Thomas Phd Adams | director | |
Gabriel Cerrone | 10 percent owner | VIA SANT' ANDREA 18, MILAN L6 20121 |
John Z Sullivan-bolyai | officer: Chief Medical Officer | C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837 |
James Sapirstein | director, officer: Chief Executive Officer | 1517 SAN JACINTO, HOUSTON TX 77002 |
Arnold Lippa | director | C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016 |
William Karl Hornung | officer: Chief Financial Officer | C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170 |
From GuruFocus
By sperokesalga sperokesalga • 05-19-2023
By Marketwired • 09-06-2023
By sperokesalga sperokesalga • 03-30-2023
By sperokesalga sperokesalga • 05-22-2023
By sperokesalga sperokesalga • 02-09-2023
By Value_Insider Value_Insider • 11-04-2022
By Marketwired • 09-29-2023
By sperokesalga sperokesalga • 05-10-2023
By Value_Insider Value_Insider • 10-26-2022
By sperokesalga sperokesalga • 03-17-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.